Thyroid and Bone: Osteoporosis, Over-replacement, and Fracture Risk

TSH suppression — whether intentional (after thyroid cancer) or accidental (over-replacement on levothyroxine) — is a recognized risk factor for accelerated bone loss and fractures, especially in postmenopausal women. Over-replacement is the single most common preventable cause of secondary osteoporosis in thyroid patients. Adequate calcium, vitamin D, and weight-bearing exercise help.

Why thyroid hormone affects bone

Bone is not static tissue. It is constantly being broken down by osteoclasts and rebuilt by osteoblasts in a coupled cycle called remodeling. Thyroid hormone — specifically T3 — is a direct regulator of that cycle. T3 binds receptors on bone cells and accelerates osteoclast activity, shortening the remodeling cycle and tipping the balance toward net resorption when levels run high [C3][C5].

In the normal adult skeleton this is invisible. The system is calibrated for a TSH in roughly the 0.5–2.5 mIU/L range, and bone turnover proceeds at a steady pace [C1]. When TSH drops below that — because endogenous thyroid hormone is too high (subclinical or overt hyperthyroidism), or because the levothyroxine dose is more than the patient needs — bone resorption outpaces formation. Over months and years this shows up as lower bone mineral density (BMD), and in vulnerable patients as fragility fractures [C2][C3][C5].

The clinical evidence for this is consistent enough that the major societies treat low TSH — even when free T4 is normal — as a bone risk factor in its own right [C1][C2][C3].

The clinical pattern: who is at risk and when

Several specific scenarios concentrate the risk of thyroid-related bone loss [C2][C3][C5]:

• Intentional TSH suppression after thyroid cancer. Patients treated for differentiated thyroid cancer are often kept at TSH below 0.1 mIU/L for years to lower recurrence risk. This is a deliberate trade-off that the endocrinology team is monitoring [C2].
• Accidental over-replacement on levothyroxine. This is the much more common scenario. A patient on a stable dose can become over-replaced after weight loss, age-related dose reduction needs, switching brand-to-generic, or starting a medication that boosts free T4 — and the suppressed TSH may go unrecognized for years [C1][C7].
• Postmenopausal women. Estrogen normally restrains osteoclast activity. After menopause that brake is released, and any additional resorptive signal — including low TSH — has a larger effect on BMD [C3][C4][C6].
• Older adults. Bone remodeling efficiency falls with age regardless of sex. The American Thyroid Association explicitly recommends a higher TSH target in older patients, partly for this reason [C1].
• Subclinical hyperthyroidism. Patients with TSH below the reference range and normal free T4 still show measurable BMD loss and an elevated fracture rate in meta-analyses, particularly at the hip [C3].
• Hashimoto's patients with poor diet quality. A recent review highlights that the dietary patterns common in chronic autoimmune thyroid disease (lower dairy, lower calcium, lower vitamin D intake) compound the underlying risk [C6].

What recovers when the dose is correct

When over-replacement is identified and the levothyroxine dose is reduced so that TSH returns to the target range, the bone effects stabilize. BMD does not usually drop further once the resorptive signal is removed, and in younger patients it can partially recover over 12 to 24 months. In postmenopausal women, recovery is slower and often incomplete — but the trajectory at least flattens [C3][C5].

The timeline of normalization is gradual [C1][C5]:

• Weeks 6–8 after dose adjustment: TSH and free T4 restabilize in the target range
• Months 6–12: bone turnover markers (when measured) normalize
• Years 1–2: DEXA-measured BMD stabilizes; partial gain possible in pre-menopausal patients

This is the strongest argument for dosing carefully in the first place. Bone density lost over years of low TSH does not fully return.

When bone loss persists despite normal TSH

If a thyroid patient has documented osteoporosis or repeat fractures and TSH is now in target, the differential broadens [C5]:

1. Coexisting menopause-related bone loss. This is the largest non-thyroid contributor in women over 50 and may need standard osteoporosis treatment (bisphosphonate, denosumab) regardless of thyroid status [C3][C4].
2. Long PPI use, glucocorticoids, SGLT2 inhibitors, or aromatase inhibitors. All increase bone loss and are common in patients with multiple chronic conditions [C5].
3. Vitamin D deficiency. Below 20 ng/mL increases fracture risk independently and is over-represented in Hashimoto's [C6]. See our vitamin-d-hashimotos article.
4. Inadequate calcium intake. Common in patients who avoid dairy because of the levothyroxine timing rule — but the rule is about timing, not avoidance [C6]. See calcium-iron-levothyroxine.
5. Primary hyperparathyroidism or celiac disease. Both can mimic "thyroid bone loss" and need their own workup if BMD continues to decline.
6. History of long-term TSH suppression. Years of low TSH leave a structural deficit that does not fully reverse, even after the TSH normalizes [C3][C5].

What does NOT help

Several heavily marketed approaches lack evidence for thyroid-related bone loss [C1][C5]:

• "Thyroid bone support" multivitamin blends. Usually contain iodine and kelp, which can destabilize Hashimoto's, plus megadose biotin that interferes with thyroid lab measurement.
• Strontium supplements. Strontium artificially inflates DEXA readings without genuinely improving bone strength, and the only approved strontium drug was withdrawn in Europe over cardiac risk.
• Switching to "natural desiccated thyroid" in the hope of reducing fracture risk. NDT contains both T4 and T3 and is more difficult to titrate precisely, which can increase the risk of unrecognized over-replacement [C1].
• High-dose vitamin A. Megadoses (above 10,000 IU/day from supplements) have been associated with reduced BMD in observational studies.
• Sustained low TSH "to feel better." Some patients prefer the energy boost of mild over-replacement; the trade-off in long-term bone and cardiac risk is documented and not negotiable in the guidelines [C1][C2].

Practical guidelines

1. Know your TSH target. For most hypothyroid adults the goal is 0.5–2.5 mIU/L; for older adults 1–4 mIU/L is often more appropriate; cancer-suppression patients have a separately set lower target [C1][C2].
2. Have TSH checked at least yearly on a stable dose — more often after any dose change, weight change, pregnancy, or medication change [C1][C8].
3. Ask for a DEXA scan if TSH is intentionally kept below 0.5 mIU/L, especially after menopause. Frequency is set by the endocrinology team based on baseline density and other risk factors [C2][C3].
4. Get 1,000–1,200 mg calcium per day from food first (dairy, fortified plant milks, leafy greens, tofu, sardines), timing the bulk of it away from the morning levothyroxine dose [C6]. See calcium-iron-levothyroxine.
5. Maintain vitamin D in the 30–50 ng/mL range — your endocrinologist will set the supplement dose based on your level [C6]. See vitamin-d-hashimotos.
6. Add weight-bearing and resistance exercise at least 2–3 times per week. This is one of the few interventions that builds bone after the menopause transition.
7. Flag any new fragility fracture to your endocrinologist — wrist, hip, or vertebral fractures from low-trauma events warrant a fresh look at TSH and a bone workup [C5].

Frequently asked questions

Does levothyroxine cause osteoporosis? A correctly dosed levothyroxine that keeps TSH in the target range does not cause osteoporosis. An over-replaced dose that keeps TSH below the reference range does increase bone loss and fracture risk over time, especially in postmenopausal women [C1][C5][C7].

My TSH is 0.3 mIU/L — should I worry about my bones? A TSH between 0.1 and 0.4 mIU/L (mild suppression) has a measurable but smaller effect on BMD than TSH below 0.1 mIU/L. Your endocrinologist will weigh symptom control against bone risk; in older adults or postmenopausal women, dose reduction is often considered [C1][C3].

How often should I get a DEXA scan if I'm on TSH suppression for thyroid cancer? There is no single universal interval, but most endocrinology centers obtain a baseline DEXA when long-term suppression begins, then repeat every 1–2 years in postmenopausal women and every 2–3 years in pre-menopausal women and men. Your team sets the interval based on your baseline [C2][C3].

Can bone density recover if I lower my dose? Bone turnover markers normalize within months. Measurable BMD recovery on DEXA is partial and slow — younger patients may regain density over 1–2 years; postmenopausal patients usually only see the loss flatten out rather than reverse [C3][C5].

Does Hashimoto's itself cause bone loss? Untreated hypothyroidism actually slows bone turnover (the opposite problem). The bone-loss signal in Hashimoto's almost always comes from the levothyroxine dose being slightly too high, plus the menopause transition that often coincides with diagnosis [C1][C6].

Bottom line

T3 directly accelerates osteoclast activity, so any sustained low TSH — from over-replacement, intentional suppression, or untreated hyperthyroidism — drives accelerated bone loss and elevated fracture risk, with postmenopausal women most exposed [C2][C3][C5]. The single most preventable cause is unrecognized levothyroxine over-replacement; the fix is annual TSH checks, dose adjustments to keep TSH in the target range, and a DEXA scan when suppression is intentional [C1][C2][C8]. Calcium from food, vitamin D in range, and weight-bearing exercise are the additional levers. "Thyroid bone support" supplements are not [C5][C6].

Sources

1. [C1] Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–1751. PubMed: 25266247
2. [C2] Ross DS et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–1421. PubMed: 27521067
3. [C3] Biondi B et al. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015;4(3):149–163. PubMed: 26558232
4. [C4] Zhu X et al. A systematic review of the relationship between normal range of serum thyroid-stimulating hormone and bone mineral density in the postmenopausal women. 2023. PubMed: 37407957
5. [C5] Gasser RW. Drug-Induced Osteoporosis. 2026. PubMed: 41682673
6. [C6] Vergatti A et al. Are Dietary Habits the Missing Link Between Hashimoto's Thyroiditis and Osteoporosis? 2025. PubMed: 40647212
7. [C7] Baskaran BS et al. Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review. 2026. PubMed: 41559017
8. [C8] American Thyroid Association. Hypothyroidism — Patient Information. thyroid.org

---

For educational purposes only. Not medical advice. Always consult your healthcare provider.